Real-world study confirms long-term safety of Enjaymo for CAD

Enjaymo (sutimlimab-jome) remains safe to use over the long term, according to new real-world data from adults with primary or secondary cold agglutinin disease (CAD) who have been taking the approved medication for an average of more than two…

Continue Reading